IDiyas

For the Inventor, By the Inventor

Groton, CT, United States of America

Benjamin A Thuma

USPTO Granted Patents = 12

Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 60(Granted Patents)


Location History:

  • Groton, CT (US) (2009)
  • Old Lyme, CT (US) (2016 - 2023)

Company Filing History:

goldMedal12 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal1 out of 15,458 
 
University of California
 patents
where one patent can have more than one assignee

Years Active: 2009-2023

Loading Chart...
12 patents (USPTO):
1. 11634410 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2023-04-25),
2. 10988463 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2021-04-27),
3. 10851367 - Tissue-specific genome engineering using CRISPR-Cas9 (2020-12-01),
4. 10813942 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2020-10-27),
5. 10787438 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2020-09-29),
6. 10376531 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2019-08-13),
7. 10174007 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2019-01-08),
8. 10039778 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2018-08-07),
9. 9809579 - Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors (2017-11-07),
10. 9617293 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2017-04-11),
11. 9340553 - Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR (2016-05-17),
12. 7615651 - Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof (2009-11-10),

Title: The Innovative Contributions of Benjamin A. Thuma

Introduction

Benjamin A. Thuma is a notable inventor based in Groton, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of ketohexokinase inhibitors. With a total of 12 patents to his name, Thuma's work has had a considerable impact on medical research and treatment options.

Latest Patents

Thuma's latest patents include the development of substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors. These patents detail processes for creating these compounds and methods for administering them to mammals in need. The innovative nature of these compounds showcases Thuma's commitment to advancing medical science.

Career Highlights

Throughout his career, Benjamin A. Thuma has worked with prominent organizations such as Pfizer Corporation and the University of California. His experience in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his contributions to innovation.

Collaborations

Some of Thuma's notable coworkers include Spiros Liras and Vincent Mascitti. Their collaborative efforts have played a crucial role in the development of his patented inventions.

Conclusion

Benjamin A. Thuma's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations continue to influence medical research and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…